PharmaVoice 100: Page 3

  • A portrait of Matt Clark framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Matt Clark
    Image attribution tooltip
    Profile // PharmaVoice 100

    Tech Wizards: Matt Clark

    X-Chem’s CEO has pioneered DNA-encoded libraries to revolutionize small molecule discovery.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Dr. Jula Inrig framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Jula Inrig
    Image attribution tooltip
    Profile // PharmaVoice 100

    Innovators: Dr. Jula Inrig

    The longtime devotee to kidney disease research is using a novel trial design to advance treatments for rare conditions at Travere.

    By • Sept. 6, 2022
  • A portrait of Dr. Judith Klimovsky framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Judith Klimovsky
    Image attribution tooltip
    Profile // PharmaVoice 100

    Innovators: Dr. Judith Klimovsky

    The executive vice president and chief business officer of Genmab is using decades of experience in oncology R&D to fuel advances in antibody-drug conjugates. 

    By • Sept. 6, 2022
  • A portrait of Dr. Pam Diamond framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Pam Diamond
    Image attribution tooltip
    Profile // PharmaVoice 100

    DE&I Champions: Dr. Pam Diamond

    The chief medical officer and co-founder of Curavit Clinical Research is bringing a new level of inclusiveness to clinical trials.

    By • Sept. 6, 2022
  • A portrait of Samantha Du framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Samantha Du
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: Samantha Du

    The CEO of Zai Lab is at the forefront of the movement to boost innovation in China’s biotech sector while delivering needed solutions to patients around the world.

    By • Sept. 6, 2022
  • A portrait of Dr. Edward Kaye framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Edward Kaye
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Dr. Edward Kaye

    The CEO behind the first genetic therapy for Duchenne muscular dystrophy is looking to extend his winning streak at Stoke.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Elisha Hughes framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Elisha Hughes
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Elisha Hughes

    The director of research biostatistics at Myriad Genetics is looking to stretch the boundaries of science and change how breast cancer is detected in diverse patient populations.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Fahti Khosrowshahi framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Fahti Khosrowshahi
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Fahti Khosrowshahi

    The president, CEO and founder of Ceek Women’s Health is on a mission to upend the OBGYN market.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Faraz Ali framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by NASDAQ
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Faraz Ali

    The CEO is leading Tenaya Therapeutics forward in ways that combine people-focused leadership, a strong dedication to patients and bold ideas for the future.

    By Alexandra Pecci • Sept. 6, 2022
  • A portrait of Frank Lee framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Frank Lee
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Frank Lee

    At Forma Therapeutics, the CEO and president is placing patients in leadership roles to weave patient centricity into the company’s business and development model.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Giacomo Chiesi framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Giacomo Chiesi
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Giacomo Chiesi

    For the head of Chiesi Global Rare Diseases, patient centricity is in his DNA.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Helen Sabzevari framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Helen Sabzevari
    Image attribution tooltip
    Profile // PharmaVoice 100

    Tech Wizards: Helen Sabzevari

    The CEO of Precigen is on a mission to develop next-generation gene and cell therapies for cancers, autoimmune disorders and more.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Dr. Jordan Schecter framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Jordan Schecter
    Image attribution tooltip
    Profile // PharmaVoice 100

    Innovators: Dr. Jordan Schecter

    The VP of cellular therapy at Janssen has used collaboration, creative thinking and pragmatism to create a CAR-T multiple myeloma breakthrough.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Matt Walz framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Matt Walz
    Image attribution tooltip
    Profile // PharmaVoice 100

    Tech Wizards: Matt Walz

    The innovative CEO is driving global clinical trial enrollment with a novel approach for the industry.   

    By • Sept. 6, 2022
  • A portrait of Dominique Demolle framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dominique Demolle
    Image attribution tooltip
    Profile // PharmaVoice 100

    Tech Wizards: Dominique Demolle

    How the CEO of Cognivia is revolutionizing drug development with psychonomics.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Dawn Berry framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dawn Berry
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: Dawn Barry

    The co-founder and president of LunaPBC is seeking to eliminate the middlemen in drug development by connecting patients — and their real-world data — directly with researchers.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Kuldeep Singh Rajput framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Kuldeep Singh Rajput
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: Kuldeep Singh Rajput

    Bringing digital solutions to Big Pharmas adapting to a more patient-centric age, the CEO and founder of Biofourmis has instituted a flexible approach that keeps its tech on the leading edge.

    By • Sept. 6, 2022
  • A portrait of David Katz framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by David Katz
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: David Katz

    As the founder and chief scientific officer of Sparrow Pharmaceuticals, David Katz is breathing new life into drugs that have previously been shelved.

    By • Sept. 6, 2022
  • A portrait of Dr. Cristian Massacesi framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Cristian Massacesi
    Image attribution tooltip
    Profile // PharmaVoice 100

    Innovators: Dr. Cristian Massacesi

    With the goal of redefining how medicines are made, the CMO and oncology CDO is transforming AstraZeneca’s oncology development.

    By • Sept. 6, 2022
  • A portrait of John Oyler framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by John Oyler
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: John Oyler

    The CEO of BeiGene is using innovative business strategies to help the oncology biotech quickly hit new heights.

    By • Sept. 6, 2022
  • A portrait of Dr. Laura Niklason framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Laura Niklason
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: Dr. Laura Niklason

    The founder, president and CEO of Humacyte is turning science fiction into regenerative medicine reality.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Maureen Hennessey framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Maureen Hennessey
    Image attribution tooltip
    Profile // PharmaVoice 100

    DE&I Champions: Maureen Hennessey

    The senior vice president, director of value transformation at PRECISIONvalue is moving the needle on patient nonadherence challenges.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Nello Mainolfi framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Nello Mainolfi
    Image attribution tooltip
    Profile // PharmaVoice 100

    Entrepreneurs: Nello Mainolfi

    Kymera Therapeutics’ CEO is chasing untreated disease targets by advancing a game-changing technology.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Chris Round framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Chris Round
    Image attribution tooltip
    Profile // PharmaVoice 100

    Legacy Leaders: Chris Round

    The president of EMD Serono, the U.S. and Canadian healthcare business unit of Merck KGaA, Darmstadt, Germany, has the company firing on all cylinders for near- and long-term growth.

    By PharmaVoice staff • Sept. 6, 2022
  • A portrait of Charlene Stern framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Charlene Stern
    Image attribution tooltip
    Profile // PharmaVoice 100

    Disrupters: Charlene Stern

    How the chief lawyer of Editas Medicine is using a multi-lens approach to bolster the development of game-changing genomic medicines.

    By PharmaVoice staff • Sept. 6, 2022